73 results on '"Attard P"'
Search Results
2. Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
3. The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer
4. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer
5. Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)
6. Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison
7. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study
8. Guidelines for genetic testing in prostate cancer: a scoping review
9. Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database
10. Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies
11. Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis
12. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
13. Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials
14. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer
15. Application of next-generation imaging in biochemically recurrent prostate cancer
16. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification
17. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy
18. The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy
19. The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review
20. Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer
21. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer
22. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada
23. Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD
24. Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
25. LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial
26. Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis
27. Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer
28. Advances in PSMA-targeted therapy for prostate cancer
29. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)
30. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
31. Clinical significance of STEAP1 extracellular vesicles in prostate cancer
32. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2–ERG fusions
33. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience
34. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
35. Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer
36. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy
37. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
38. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies
39. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study
40. Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study
41. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
42. Androgen receptor variant-driven prostate cancer II: advances in clinical investigation
43. Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
44. Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer
45. Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI
46. Annual Acknowledgement of Manuscript Reviewers
47. Role of the DNA damage response in prostate cancer formation, progression and treatment
48. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer
49. Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer
50. PTEN status assessment in the Johns Hopkins active surveillance cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.